Who is sponsoring NCT06733610?

NCT06733610 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT06733610?

Interventions in NCT06733610: universal allogeneic anti-CD19/BCMA CAR T-cells.

What condition does NCT06733610 study?

NCT06733610 studies Autoimmune Hemolytic Anemia, CD19/BCMA CAR T-cells, Universal Allogeneic CAR T-cells.

Is NCT06733610 still recruiting?

NCT06733610 is currently recruiting now. Last updated 13 December 2024.

Last reviewed 2024-12-13 · How we verify

NCT06733610

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

Recruiting now Phase 1 Last updated 13 December 2024

What this trial tests

Phase 1 trial testing universal allogeneic anti-CD19/BCMA CAR T-cells in Autoimmune Hemolytic Anemia in 15 participants. Currently enrolling.

Timeline

5 December 2024

Primary endpoint
5 February 2026

5 December 2026

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	5 December 2024
Primary completion	5 February 2026
Estimated completion	5 December 2026
Sites	1 location across China

Drugs / interventions tested

universal allogeneic anti-CD19/BCMA CAR T-cells — full drug profile →

Conditions studied

Autoimmune Hemolytic Anemia — all drugs for Autoimmune Hemolytic Anemia →
CD19/BCMA CAR T-cells — all drugs for CD19/BCMA CAR T-cells →
Universal Allogeneic CAR T-cells — all drugs for Universal Allogeneic CAR T-cells →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

18 and older, any sex, with Autoimmune Hemolytic Anemia or CD19/BCMA CAR T-cells. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.
Wu D, Xu-Monette ZY, Zhou J, Yang K, et al · · 2025 · cited 9× · PMID 40873568 · DOI 10.3389/fimmu.2025.1613878
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.
Chen X, Liu K, Liu B, Li S, et al · · 2025 · cited 4× · PMID 41316450 · DOI 10.1186/s13045-025-01769-0
Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.
Alsayb MA. · · 2025 · cited 2× · PMID 41041324 · DOI 10.3389/fimmu.2025.1647066
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4
Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug.
Schenk HCM, Gille I, Arana C, Rovira J, et al · · 2026 · cited 1× · PMID 41514167 · DOI 10.1111/tan.70550
Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.
Osborne M, Maher J. · · 2025 · PMID 41463563 · DOI 10.3390/biology14121790

Verify or expand the search:

Other recruiting trials for Autoimmune Hemolytic Anemia

Currently open trials in the same condition.

NCT07441525 — UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases · EARLY_PHASE1 · recruiting
NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
NCT06921980 — Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia · recruiting
NCT06888960 — Safety Study of CC312 in Autoimmune Disease Patients · EARLY_PHASE1 · recruiting
NCT06231368 — CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. · Phase 1 · active not recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06733610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 13 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06733610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing